内分泌科

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. A Survey of Pheochromocytoma and Paraganglioma Patient Environment

   Rochester, Minn.

   The purpose of this study is to determine the association of environmental, geographic factors, as well as presence of comorbidities associated with hypoxia with development of pheochromocytomas and paragangliomas (PPGL), location of PPGL, and number of PPGL.

    

2. A Study of Bone Microstructure and Bone Strength Using High-Resolution CT Scanning in Adults with Repeat Fractures

   Rochester, Minn.

   The purpose of this study is to obtain more detailed information about bone structure in adults with repeat bone fractures.

    

3. A Study to Evaluate the Effect of Improving Glycemic Control on Gastric Emptying in Type 1 and Type 2 Diabetes Mellitus

   Rochester, Minn.

   The purpose of this study is to evaluate the effects of improving glycemic control, and/or reducing glycemic variability on gastric emptying, intestinal barrier function, autonomic nerve functions, and epigenetic changes in subjects with type 1 diabetes mellitus (T1DM) and  type 2 diabetes mellitus (T2DM) who are switched to intensive insulin therapy as part of clinical practice.

4. Correlation of Pancreatic Islet Morphology with Postprandial Glucose Tolerance in Subjects Undergoing Pancreatic Resection for Islet Cell Tumors

   Rochester, Minn.

   Determine the effect of endocrine pancreas morphology, turnover and dedifferentiation on glucose tolerance in humans. 

5. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.

6. A Study to Assess Maternal and Fetal Outcomes in Pregnancy with Type 1 Diabetes Mellitus and Controls

   Rochester, Minn.

   The purpose of this study is to retrospectively and prospectively compare maternal and fetal/newborn clinical outcomes in age-matched pregnant patients with T1D and healthy controls and to assess the relationship between glycemic variability and pregnancy outcomes in the current era.

7. Neuroendocrine Tumors - Patient Reported Outcomes

   Rochester, Minn.

   The purpose of this study is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for patients with Neuroendocrine Tumors (NET).

8. Obesity Treatment Outcomes in Liver Transplant Recipients

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to prospectively evaluate the safety and effectiveness of standard of care, individualized, comprehensive weight loss interventions in carefully selected patients with obesity undergoing liver transplant evaluation, including utilization of best lifestyle modifications and guidance to promote a healthy weight, possible medical therapy using FDA-approved weight loss medications and EBMTs with or without concomitant medical therapy.

9. Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

10. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

    Rochester, Minn.

    The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. A Survey of Pheochromocytoma and Paraganglioma Patient Environment

   Rochester, Minn.

   The purpose of this study is to determine the association of environmental, geographic factors, as well as presence of comorbidities associated with hypoxia with development of pheochromocytomas and paragangliomas (PPGL), location of PPGL, and number of PPGL.

    

2. A Study of Bone Microstructure and Bone Strength Using High-Resolution CT Scanning in Adults with Repeat Fractures

   Rochester, Minn.

   The purpose of this study is to obtain more detailed information about bone structure in adults with repeat bone fractures.

    

3. A Study to Evaluate the Effect of Improving Glycemic Control on Gastric Emptying in Type 1 and Type 2 Diabetes Mellitus

   Rochester, Minn.

   The purpose of this study is to evaluate the effects of improving glycemic control, and/or reducing glycemic variability on gastric emptying, intestinal barrier function, autonomic nerve functions, and epigenetic changes in subjects with type 1 diabetes mellitus (T1DM) and  type 2 diabetes mellitus (T2DM) who are switched to intensive insulin therapy as part of clinical practice.

4. Correlation of Pancreatic Islet Morphology with Postprandial Glucose Tolerance in Subjects Undergoing Pancreatic Resection for Islet Cell Tumors

   Rochester, Minn.

   Determine the effect of endocrine pancreas morphology, turnover and dedifferentiation on glucose tolerance in humans. 

5. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.

6. A Study to Assess Maternal and Fetal Outcomes in Pregnancy with Type 1 Diabetes Mellitus and Controls

   Rochester, Minn.

   The purpose of this study is to retrospectively and prospectively compare maternal and fetal/newborn clinical outcomes in age-matched pregnant patients with T1D and healthy controls and to assess the relationship between glycemic variability and pregnancy outcomes in the current era.

7. Neuroendocrine Tumors - Patient Reported Outcomes

   Rochester, Minn.

   The purpose of this study is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for patients with Neuroendocrine Tumors (NET).

8. Obesity Treatment Outcomes in Liver Transplant Recipients

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to prospectively evaluate the safety and effectiveness of standard of care, individualized, comprehensive weight loss interventions in carefully selected patients with obesity undergoing liver transplant evaluation, including utilization of best lifestyle modifications and guidance to promote a healthy weight, possible medical therapy using FDA-approved weight loss medications and EBMTs with or without concomitant medical therapy.

9. Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

10. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

    Rochester, Minn.

    The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.